Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets

Xiong, Yan, Zhong, Yue, Yim, Hyerin, Yang, Xiaobao, Park, Kwang-Su, Xie, Ling, Poulikakos, Poulikos I., Han, Xiaoran +4 more·2022·Journal of the American Chemical Society
DOI 10.1021/jacs.2c09255

Cited by (154)

Items 101–154 of 154

  1. Simple and ultra-fast detection of protein-small molecule interaction using Argonaute sensing platform
    Xiangyan Dong, Hui Chen, Zexu Hu, Ying Feng, Peiyi Zhang, Fangxi Zhao, Xiaopeng Wang, Decai Yuan, Tingting Fan, Feng Liu et al. · 2025 · Sensors and Actuators B Chemical
  2. Degraders of cell cycle- and antiapoptosis-related proteins
    Yingqiong Zhang, Rong Dong, Bo Zhang · 2025 · Elsevier eBooks
  3. Structural diversification and selective inhibition of HDAC3: A comprehensive review of inhibitors and degraders
    Jin-Ying Liu, Yuan Quan, Ya-Lan Wang, Wen-Zhe Nie, Cheng-mei Cui, Binshan Zhao, Nan-nan Cui, Qing-bei Lian, Gao Li, Qing‐Kun Shen · 2026 · European Journal of Medicinal Chemistry
  4. Carborane Hydrophobic Tags Drive Selective Degradation of Endogenous KRASG12C via HSP70–Ubiquitin–Proteasome Pathway
    Yujie Shao, Kazuki Miura, Hiroyuki Nakamura · 2026 · ACS Bio & Med Chem Au
  5. Antibacterial PROTACs: the road ahead for next-generation antibiotics?
    Andrea Milelli, Simone Raimondi, Somayeh Asgharpour, Jean‐Denis Docquier, Francesca Spyrakis · 2026 · Drug Discovery Today
  6. Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review
    Shaik Abdul Rahaman, Garla Venkateswarlu, Sakshi Patel, Prem Shankar Mishra, Rahul Kumar, Nayyar Parvez · 2026 · Current Topics in Medicinal Chemistry
  7. Redirecting TRIM21 with TRIMTACs for the targeted degradation of multimeric proteins
    Marc A Scemama de Gialluly, Drew Adams · 2026 · FEBS Journal
  8. E3 ubiquitin ligases in neurodegenerative diseases
    Duan Lu Hou, Josephine Ho, Tuchen Guan, Xiao-Xue Dong, Li Zeng, Laurie H. Sanders, Y Wu, Eng‐King Tan, Zhi Dong Zhou · 2026 · Military Medical Research
  9. Targeted proteoform degradation for precision drug design, delivery, and therapy
    Chen-Yu Cui, Hao-Yue Zhang, Xinmiao Wang, Na Li, Xian-Quan Zhan · 2026 · Drug Delivery
  10. E3 ubiquitin ligases in bone homeostasis: from regulatory mechanisms to skeletal diseases and therapeutic targeting
    Yutong Zhao, 曹楠珏, Wenxiao Yang, Yuanfang Wang, Wei Wang · 2026 · Frontiers in Cell and Developmental Biology
  11. On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases
    Janik Weckesser, Nebojša Miletić, Saran Aswathaman Sivashanmugam, Uli Ohmayer, Martin Steger, Bachuki Shashikadze, Paul Gehrtz, Andrea Unzue Lopez, Ansgar A. Wegener, T J Dietz et al. · 2026 · Journal of Medicinal Chemistry
  12. CDK4/6-targeted therapy: From clinical inhibitors to emerging strategies to overcome resistance
    Wenjie Sha, Dijing Feng, Zitong Yan, Zhuo Chen, Ying Lu · 2026 · Bioorganic & Medicinal Chemistry
  13. From undruggable to degradable: development of anthraquinone-based PROTACs against MITF for skin-lightening applications
    Meng Xu, Zi-Qing Zhang, Peixi Zhang, Xin-Yi He, Xin-Yue Pan, Cai-Xia Huang, Yan-jun DI, Yan Wang, Jie‐Qing Liu · 2026 · Journal of Asian Natural Products Research
  14. Covalent Bifunctional Molecules (CBMs): Achievements and Challenges
    Yuting Xin, Fangsu Chen, Qidong You, Lei Wang, Qiuyue Zhang · 2025 · Medicinal Research Reviews
  15. DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation
    Rong Zheng, Abhay Prasad, Deeksha Satyabola, Yang Xu, Hao Yan · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  16. Characterization of MEK1/2 Degraders Uncovers a Kinase-Independent Role for MEK1/2 in the Stabilization and Maturation of CRAF
    Jason S. Wasserman, Alison Kurimchak, Carlos Herrera-Montávez, Glenn A. R. Doyle, Brandon D. Fox, Ishadi K. M. Kodikara, Xiaoping Philip Hu, Jianping Hu, Jian Jun Jin, James S. Duncan · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  17. WITHDRAWN: MEK1/2-Targeting PROTACs Promote the Collateral Degradation of CRAF in KRAS Mutant Cells
    Carlos Herrera-Montávez, Alison Kurimchak, Xiaoping Hu, Jianping Hu, Jian Jun Jin, James S. Duncan · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  18. Simple and Efficient Synthesis of Piperidine-2,6-Diones
    Yuehua Liu, Zhang‐Qin Xue, Kai-Wen Yang, Hao‐Wen Yin, Tian‐Zhang Wang, Yu‐Qiu Guan, Yu-Feng Ligang, Hao Zhong, Zhushuang Bai · 2023 · SSRN Electronic Journal
  19. Palbociclib, ribociclib, and abemaciclib: potent and selective CDK4/6 inhibitors for the treatment of breast cancer
    Kai Yuan, Weijiao Chen, Xiao Wang, Peng Yang · 2024 · Elsevier eBooks
  20. PROTACs of cyclin-dependent kinases
    Denisa Veselá, Eva Řezníčková, Václav Mik, Radek Jorda · 2024 · Annual reports in medicinal chemistry
  21. Characterization of Homeodomain Proteins at the Aβ Sublocus in Schizophyllum commune and Their Role in Sexual Compatibility and Development
    Chen Chu, Dongxu Li, Changhong Liu · 2025 · Journal of Fungi
  22. Lysosome-mediated degradation
    Wenhai Huang · 2025 · Elsevier eBooks
  23. Ubiquitin-dependent degradation of p21 Waf1/Cip1 is mediated by AMBRA1 to limit DNA replication stress
    Giacomo Milletti, Giulia Cadeddu, Alba Adelantado-Rubio, Caterina Ferraina, Kristina Keuper, Sebastian Howen Nesgaard Munk, Cristiano De Stefanis, Denise Quacquarini, Sabrina Rossi, Angela Mastronuzzi et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  24. Inhibitors and degraders of epigenetic regulation in cancer
    Pengcheng Gao, H. Ümit Kanıskan, Jian Jin · 2025 · Elsevier eBooks
  25. Tricarbonyl Rhenium‐Based PROTACs Degrade the SARS‐CoV‐2 Mpro Protease
    Liuruiqi Luo, Yuxiang Lu, He Meng, Wenkai Lin, Kai Lu, Jing Wang, Jinghui Wang, Yufang Xiong, Zong‐Wan Mao, Wei Ting Xia · 2025 · Chemistry - A European Journal
  26. Degradation of Cyclin-Dependent Kinase: A New Weapon for Cancer Therapy
    Xing Tian, Xiaojie Dai, Ye Zhong, Maosheng Cheng, Yang Liu · 2025 · Pharmaceutical Fronts
  27. PROTAC-based degradation of catechol-O-methyltransferase for potential treatment of Parkinson’s disease
    Haixiao Fang, Panpan Li, Qi Gao, Shubo Du, Jing Gu, Xia Liu, Bo Peng, Hua Bai, Cheng-Wu Zhang, Lin Li et al. · 2026 · Science China Chemistry
  28. PROTACs for Collateral Degradation: Is It Time to Back Up the Bus?
    Zhe Gavin Gao, Kevin Burgess · 2026 · ACS Medicinal Chemistry Letters
  29. Opportunities and challenges in targeted protein degradation for antiviral drug discovery
    Man Zhu, Maoze Yang, Hai‐Bing Zhou · 2026 · Elsevier eBooks
  30. PROTAC-mediated regulation of programmed cell death: From molecular mechanisms to therapeutic breakthroughs
    Hangqi Huang, Aoli Deng, Feifan Pan, Yajuan Lu, Lulu Chen, Jinghao Cao, Qin Tang, Yingchao Liu, Yunyi Wu, Jing Du et al. · 2026 · The Innovation
  31. Targeting enzymes through PROTAC-mediated degradation: When is a PROTAC better than a small molecule inhibitor?
    Samuel W. Gerritz, Ann-Marie Campbell, Dana M. Klug, Dan Sherman · 2026 · Elsevier eBooks
  32. Senolytic effects of first and second generation BCL-xL/BCL-2 dual degraders
    E. S. Berezhnaya, A. V. Savustyanenko · 2026 · Pharmacy & Pharmacology
  33. Ubiquitin-dependent degradation of p27Kip1 and p21Waf1/Cip1 by AMBRA1 ensures G1 and S phase progression and limits replication stress
    Giacomo Milletti, Giulia Cadeddu, Alba Adelantado-Rubio, Caterina Ferraina, Kristina Keuper, Sebastian Howen Nesgaard Munk, Cristiano De Stefanis, Denise Quacquarini, Sabrina Rossi, Angela Mastronuzzi et al. · 2026 · Nucleic Acids Research
  34. PROTAC‐Armed Electron Pump Triggers Disulfidptosis and Cuproptosis for Lung Cancer Therapy
    Yu Wang, Min Zhang, Zhao Yang, Juan Ruan, Wenjun Zhang, Shuo Shi · 2026 · Advanced Functional Materials
  35. Modular Access to Diverse Soluble Epoxide Hydrolase Degraders as Potential Agents for Alleviating LPS-Induced Acute Inflammation
    Chenxin Yin, Yu Bai, Chunxiang Li, Enqin Yang, Hou-Hua Yin, Christophe H.P. Morisseau, Qing-Jin Pan, Ping Dai, Ling Huang, Bruce D. Hammock et al. · 2026 · Journal of Medicinal Chemistry
  36. Tau-Targeted PROTACs Degrade Pathology-Associated Tau and Improve Memory in Alzheimer’s Disease Models
    Tian Zhao, Tian-Yang Wang, Hao-Sen Wang, Yeh‐Jun Lim, Zhi-Jun Zhang, Xin-Rong Duan, Li Liang, Yanmei Li · 2026 · ACS Chemical Biology
  37. A comprehensive review of the mechanism and application prospect of PARP dual-target inhibitors in tumor treatment
    Yi‐Ru Bai, Ruifang Li, Kang Jing-ru, Dong‐Jie Seng, Ying Xu, Wei-Guang Yang, Hong‐Min Liu, Shuo Yuan · 2026 · European Journal of Medicinal Chemistry
  38. Discovery of rigid linker-based CDK4/6 PROTACs for the treatment of breast cancer
    Guoyong Pan, You Li, Jinke Tan, Yuanyuan Chen, Weijiao Chen, Huanaoyu Yang, Xujie Zhuang, Linhu Shen, Ziyu Zong, Yiming Fan et al. · 2026 · Bioorganic Chemistry
  39. CDK4/6 inhibitors: drug discovery, development, and classification
    Shankar Gupta, Chahat, Bhupinder Kumar, Manvendra Kumar, Muhammad Wahajuddin, Gaurav Joshi · 2026 · Elsevier eBooks
  40. Self-sustaining ROS-responsive hydrogel enabled delivery of PROTAC/Ce6 nanoparticles via PDT-Epigenetic protein degradation to amplify pyroptosis for enhanced cancer immunotherapy
    Liming Gong, Jing Feng, Liqing Chen, Mong-Hsiu Song, Bohan Chen, Xiaolong Li, Mingji Jin, Feifei Yang, Qingyun Yang, Zhonggao Gao et al. · 2026 · Biomaterials
  41. Raman spectroscopy reveals a novel mechanism by which cyclin Y promotes breast cancer progression by regulating lipid metabolism
    Lingxian Zhang, Deyu Kong, Gang Chen, Jiayu Mei, Yaogan Luo, Wang Shi, Jiabao Xu, Cheguo Cai, Mengna Zhang · 2026 · Acta Biochimica et Biophysica Sinica
  42. Identification of Novel Acylthiourea-Based PROTACs Exhibiting Broad-Spectrum Antiviral Activity against Enteroviruses
    Yumeng Cai, Maoze Yang, Lei Yu, Jiye Tang, Tianai Fan, Jiang Wu, Qianru Wan, Ke Lan, Hai‐Bing Zhou, Shuwen Wu · 2026 · Journal of Medicinal Chemistry
  43. BeyondTACs: Chemical Editing of Posttranslational Modifications (PTMs) for Therapeutic Intervention
    Chen Zhang, Hui Ye, Yihua Zhang, Jianbing Wu, Zhangjian Huang · 2026 · Chemistry - A European Journal
  44. Protein degraders targeting JAK/STAT3 signaling pathway are emerging therapeutic modalities for human cancers
    Xinyu Feng, Nanjing Li, Xiaorong Chen, Xinyue Cao, Jingling Dai, Shaoquan Xiong, Zhu Yuan · 2026 · Biochemical Pharmacology
  45. BindingDB Entry 50021146: Targeting autophagy drug discovery: Targets, indications and development trends.
    BindingDB · 2025 · UC San Diego
  46. BindingDB Entry 50022960: Overview of PRMT1 modulators: Inhibitors and degraders.
    BindingDB · 2026 · UC San Diego
  47. BindingDB Entry 50021145: Annual review of PROTAC degraders as anticancer agents in 2022.
    BindingDB · 2025 · UC San Diego
  48. BindingDB Entry 50023187: Recent advances in developing targeted protein degraders.
    BindingDB · 2026 · UC San Diego
  49. BindingDB Entry 50014860: Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer.
    BindingDB · 2026 · UC San Diego
  50. BindingDB Entry 50023252: Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation.
    BindingDB · 2026 · UC San Diego
  51. BindingDB Entry 50023632: Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities.
    BindingDB · 2026 · UC San Diego
  52. BindingDB Entry 50021731: Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader.
    BindingDB · 2025 · UC San Diego
  53. BindingDB Entry 50023102: Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020-2024).
    BindingDB · 2026 · UC San Diego
  54. BindingDB Entry 50019409: PROTACs Targeting MLKL Protect Cells from Necroptosis.
    BindingDB · 2024 · UC San Diego